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Lili Yamasaki,* Tyler Jacks,² Roderick Bronson,³ Five highly related E2F genes (E2F-1, E2F-2, E2F-3,
Evelyne Goillot,* Ed Harlow,* E2F-4, and E2F-5) and three DP genes have been iden-
and Nicholas J. Dyson* tified in vertebrates (La Thangue, 1994; Slansky and
*Massachusetts General Hospital Cancer Center Farnham, 1995; Weinberg, 1995). Three E2F members
Building 149 (E2F-1, E2F-2, and E2F-3) associate with a DP member
13th Street and in turn bind pRB through a small 18 amino acid
Charlestown, Massachusetts 02129 interaction domain located in the carboxyl termini of the
²Howard Hughes Medical Institute E2F polypeptides (Helin et al., 1992; Kaelin et al., 1992;
Department of Biology Shan et al., 1992; Ivey-Hoyle et al., 1993; Lees et al.,
Massachusetts Institute of Technology 1993). E2F-4 and E2F-5 associate with a DP member
Center for Cancer Research and then bind the pRB-related proteins, p107 and p130
Cambridge, Massachusetts 02139 (Beijersbergen et al., 1994; Ginsberg et al., 1994; Hij-
³USDA Human Nutrition Research Center on Aging mans et al., 1995; Sardet et al., 1995; Vairo et al., 1995).
Department of Pathology E2F sites are found in the promoters of many genes
School of Veterinary Medicine intimately involved in cell cycle progression. These in-
Tufts University clude genes required for DNA replication (e.g. DHFR,
Boston, Massachusetts 02111 POLa, TK, TS and RNR), for cyclin-dependent kinase
activity (e.g. cyclins D, E, and A and cdc2), and also
Summary the nuclear oncogenes (c-myc, N-myc and b-myb), the
pocket protein genes and the E2F-1 gene (Slansky and
The retinoblastoma tumor suppressor protein (pRB) Farnham, 1995). By deletion or mutation of E2F sites in
is a transcriptional repressor that regulates gene ex- many of these promoters, it has been demonstrated
pression by physically associating with transcription that E2F sites are important for the correct temporal
factors such as E2F family members. Although pRB expression pattern of the target gene. However, given
and its upstream regulators are commonly mutated in the different times at which these target genes are ex-
human cancer, the physiological role of the pRB±E2F pressed, it is clear that distinct mechanisms must be
pathway is unknown. To address the function of responsible for the timing of their activation. For none
E2F-1 and pRB/E2F-1 complexes in vivo, we have pro- of these E2F-regulated promoters is it known which
duced mice homozygous for a nonfunctional E2F-1 E2F/DP complex regulates expression. Also, the pocket
allele. Mice lacking E2F-1 are viable and fertile, yet protein responsible for repression of specific E2F-target
experience testicular atrophy and exocrine gland dys- genes is unclear. Consequently, the complexity of the
plasia. Surprisingly, mice lacking E2F-1 develop a
E2F gene family, in conjunction with thebreadth of targetbroad and unusual spectrum of tumors. Although
genes identified, highlights the difficulty in determiningoverexpression of E2F-1 in tissue culture cells can
the actual physiological role of any individual E2Fstimulate cell proliferation and be oncogenic, loss of
member.E2F-1 in mice results in tumorigenesis, demonstrating
Clues to the function of E2Fs arise from overexpres-that E2F-1 also functions as a tumor suppressor.
sion or deregulated-expression studies. Microinjection,
transient transfection, and viral infection experimentsIntroduction
have shown that E2F-1 overexpression is sufficient to
induce DNA replication (Johnson et al., 1993; Qin et al.,E2F proteins and DP proteins comprise two families of
1994; Shan and Lee, 1994; Kowalik et al., 1995) andtranscription factors that form heterodimeric complexes
that overexpression of dominant negative E2F mutantsand confer cell cycle±specific expression to promoters
inhibits cell cycle progression from G1 to S phase (Do-containing E2F-binding sites. The timing of E2F-medi-
browolski et al., 1994). Furthermore, studies in Drosoph-ated transcription is regulated through several mecha-
ila where only a single E2F has been identified (Dynlachtnisms. E2F-mediated transcription is repressed through
et al., 1994a; Ohtani and Nevins, 1994) have demon-a physical association of E2F/DP heterodimers with pro-
strated that dE2F is required for entry into S phaseteins of the retinoblastoma family (pRB, p107, or p130
(Duronio et al., 1995). These studies suggest that E2F/collectively referred to as the ªpocketº proteins). Cyclin-
DP transcriptional activity is rate-limiting for transitiondependent kinase-mediated phosphorylation (Sherr,
from G1 into S phase. Overexpression of E2F-1 or E2F-1994) or DNA tumor virus antigen binding (Nevins, 1992)
1/DP-1 cooperates with activated ras in fibroblast trans-inactivates the pocket proteins, leading to dissociation
formation assays, and these transformed cells form tu-of the pocket protein/E2F/DP complexes, and subse-
mors in nude mice (Johnson et al., 1994a; Singh et al.,quent activation of E2F-dependent transcription. Addi-
1994; Jooss et al., 1995; Xu et al., 1995), demonstratingtionally, E2F-mediated transcription is stimulated by an
that E2F-1 can be oncogenic. Apart from the role ofE2F-regulatory loop that amplifies the expression of the
E2F-1 in stimulating proliferation, overexpression ofE2F genes themselves (Hsiao et al., 1994; Johnson et
E2F-1 in some tissue culture cells can induce apoptosisal., 1994b; Neuman et al., 1994). Finally, E2F-mediated
that is p53-dependent (Qin et al., 1994; Shan and Lee,transcription is attenuated late in S phase by cyclin-
1994; Wu and Levine, 1994; Kowalik etal., 1995). Overex-dependent kinase phosphorylation of the E2F/DP heter-
pression of E2F-1 may induce apoptosis by regulatingodimer, which results in the loss of DNA-binding activity
(Dynlacht et al., 1994b; Krek et al., 1994; Xu et al., 1994). genes important for cell survival or perhaps by driving
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cells into S phase at an inappropriate time, which may all of exon 3 in the E2F-1 locus were replaced by the
neoR gene in an antisense orientation (Figure 1A). Thisinduce apoptosis.
Similar suggestions for the function of E2Fs in regulat- deletion removes amino acid residues 89±186 of mouse
E2F-1 (Li et al., 1994; A. Talis and K. Helin, unpublisheding proliferation can be inferred from mutations in regu-
latory proteins upstream of E2F/DP function. Rb1/2 mice data), which correspond to amino acid residues 95±191
of human E2F-1. Exons 2 and 3 encode residues thatdevelop pituitary and thyroid tumors (Jacks et al., 1992;
Hu et al., 1994; Williams et al., 1994). Cyclin D overex- are known to be critical for cyclin A/cdk2 association
and DNA binding, respectively (Helin et al., 1992; Kaelinpression in the mammary epithelium of transgenic mice
produces mammary adenocarcinomas (Wang et al., et al., 1992; Shan et al., 1992; Dynlacht et al., 1994b;
Krek et al., 1994; Xu et al., 1994). Following electropora-1994). The frequent isolation of mutations in the genes
encoding pRB, cyclin D, cdk4, or the cyclin-dependent tion and double drug selection of embryonic stem cell
clones, Southern analysis revealed that homologous re-kinase inhibitor p16 from human tumors reinforces the
importance of the pRB pathway in negative growth con- combination had occurred at the E2F-1 locus at high
frequency (1/3 doubly resistant G418R/gancyclovirRtrol (Hunter, 1994; Kamb, 1995; Weinberg, 1995; Wolfel
et al., 1995). Taken together, these data strongly suggest clones or 1/17 singly resistant G418R clones). Two
E2F-1 heterozygous (1/2) clones were used to producethat E2F/DP function may be a major target for pRB-
mediated growth suppression. These data have led to male chimaeras that transmitted the mutated E2F-1 al-
lele through the germline to 50% of their agouti 129 3a widely accepted model that E2F/DP activity promotes
cell-cycle progression, and that pocket proteins sup- C57BL/6 offspring. F1 E2F-11/2 males and females were
then interbred to produce F2 litters. Genotyping bypress growth by repressing E2F/DP-mediated transacti-
vation (Nevins, 1992; La Thangue, 1994; Muller, 1995; Southern analysis (Figure 1B) or by genomic polymerase
chain reaction (PCR; Figure 1C) demonstrated thatWeinberg, 1995).
In addition to suppressing growth, pRB also appears E2F-1homozygous (2/2) mutants, heterozygotes(1/2),
and wild-type animals were produced at the expectedto inhibit apoptosis and facilitate differentiation, sug-
gesting that E2F/DP complexes may participate in these ratio of 1:2:1.
Since the E2F-12/2 animals were viable, we next con-processes as well. Rb2/2 mouse embryos die between
E14 and E16 of gestation, with increased levels of firmed that the E2F-1 protein was indeed absent. Owing
to the extremely low levels of endogenous E2F-1 expres-apoptosis in the central nervous system and fetal liver,
and display incomplete erythropoiesis (Clarke et al., sion in wild type and E2F-11/2 asynchronously growing
embryonic fibroblasts, the induction of higher levels of1992; Jacks et al., 1992; Lee et al., 1992, 1994). Neuronal
differentiation correlates with elevated levels of pRB in E2F-1 upon serum restimulation was compared be-
tween E2F-12/2 and E2F-11/2 fibroblasts. Fibroblastsembryonic carcinoma cells (Slack et al., 1993) and is
impaired in Rb2/2 embryos (Lee et al., 1994), and myo- from E2F-12/2 and E2F-11/2 embryos (E12.5) were syn-
chronized by serum starvation and restimulated withtubes from pRB-negative cells are able to reenter the
cell cycle (Gu et al., 1993; Schneider et al., 1994). These serum for 18±20 hr to induce E2F-1 expression. E2F-1
levels in the resultant lysates were monitored by immu-data underscore the delicate balance that pRB may help
maintain between proliferation, apoptosis, and differen- noprecipitation, then Western analysis with anti-E2F-1
antibodies (Figure 1D; all E2F-1 antibody reagents weretiation.
To assess the role of a single E2F in normal growth kindly provided by K. Helin). Either a monoclonal anti-
E2F-1 antibody (KH129) or a polyclonal anti-E2F peptideand developmentand to test whether E2F-1 has a critical
function in the regulation of proliferation, apoptosis, serum (anti-RBP3; Helin et al., 1992) was used for immu-
noprecipitation, followed by Western blotting with a pooland/or differentiation in vivo, we have inactivated the
E2F-1 locus in mice by homologous recombination. of two anti-E2F-1 specific monoclonal antibodies (KH22
and KH102). E2F-1 was detected with both antibodiesMice lacking E2F-1 are viable, yet several tissues are
sensitive to the absence of E2F-1. Surprisingly however, in lysates from E2F-11/2 cells, but not in E2F-12/2 cell
lysates. Both the polyclonal and monoclonal anti-the loss of E2F-1 also predisposes many of the homo-
zygous E2F-12/2 mutants to develop tumors. These E2F-1 antibodies recognize C-terminal epitopes of
E2F-1 (Helin et al., 1992; K. Helin, unpublished data).data strongly suggest that the working model in which
Thus, the absence of a signal in E2F-12/2 lysates stronglyE2F-1 functions only to drive cell proliferation is incom-
suggests that a C-terminal fragment of E2F-1 is notplete. In addition to promoting proliferation in some tis-
expressed. Conceivably, an N-terminal fragment ofsues, E2F-1 must act in some manner to suppress prolif-
E2F-1 (amino acid residues 1±88) could be expressed;eration in other tissues. Thus E2F-1 is a previously
however, since stop codons were introduced into theunrecognized tumor-suppressor protein. This illustrates
altered exon 2, this fragment would lack the DNA-bind-a novel situation in which E2F-1 can act as an oncogene
ing, heterodimerization, and pRB-binding domains ofin some settings and as a tumor suppressor in others.
E2F-1. Thus, the viability of E2F-12/2 animals occurred
in the absence of a functional E2F-1 protein.
Results E2F-12/2 females and males examined at 2.5 months
of age showed no gross anatomical or overt histological
Inactivation of the E2F-1 Locus abnormalities. However, three abnormalities became
To inactivate the E2F-1 locus by homologous recombi- obvious with increasing age in the E2F-12/2 animals.
nation (Mansour et al., 1988; Capecchi, 1989), we con- These include testicular atrophy, exocrine gland dyspla-
sia, and the development of tumors and are discussedstructed a targeting vector in which most of exon 2 and
Mice Lacking E2F-1
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Figure 1. Targeted Disruption of the E2F-1
Locus
(A) Genomic organization of the wild-type
E2F-1 allele is shown (top) with the positions
of coding exons 2±7 indicated. The targeting
vector (middle) was constructed to replace a
portion of exon 2 and all of exon 3 with the
neoR gene in an antisense orientation. The
deleted codons correspond to amino acids
89±186 in mouse E2F-1. These amino acids
are equivalent to 94±191 in human E2F-1,
which are required for cyclin A binding and
DNA binding. Homologous recombination
betweenthe wild-type allele and thetargeting
vector produced the mutant allele (bottom) in
which the thymidine kinase gene was ex-
cised.
(B) Southern analysis revealed that E2F-12/2
animals were viable and appeared at the ex-
pected frequency of 25%. After EcoRI diges-
tion, hybridization with a 39probe detects a
9.0 Kbp wild-type allele and a 9.8 Kbp mutant
allele.
(C) A genomic PCR assay was performed to
genotype all progeny. Separate PCR reac-
tions with either the E2F-1 exon 3 primer (L26)
or the neoR gene primer (L28) and an intron
primer (L31) were used to detect the wild-
type allele (392 bp) or the mutant allele (167
bp), respectively. PCR primer positions are
indicated in (A).
(D) Immunoprecipitation±Western analysis
for E2F-1. Lysates from serum-starved and
restimulated 12.5-day-old mouse embryo fi-
broblasts were immunoprecipitated with ei-
ther monoclonal (KH129) or polyclonal (anti-
RBP3 peptide) antibody reagents for E2F-1
or control reagents (PAb419 or normal rabbit serum). Western blotting with two anti-E2F-1 monoclonals that recognize unique C-terminal
epitopes of E2F-1 (KH22 and KH102) detected E2F-1 only in (1/2) lysates. Recombinant mouse E2F-1 was used as a control for Western
blotting (last lane).
in detail below. Other E2F-12/2 tissues were examined per cross-section (Figure 2C, right image). Interestingly,
the number of Leydig cells did not appear to decreaseand showed no change or only small sporadic differ-
ences. with age and in some animals appeared to increase
in number. Although the testes from E2F-12/2 animals
experiencing the most extreme atrophy appeared toTesticular Atrophy
Both E2F-12/2 males and females were fertile. However, contain many more Leydig cells, the apparent increase
may have been due to the overall reduction in testicu-all males autopsied between 9 and 15 months of age
displayed testicular atrophy (Figure 2A). The average lar size.
Testicular atrophy as judged by average testiculartestis weight for E2F-12/2 males (52 6 20 mg) was 44%
of the average testis weight for wild-type males (118 6 weight reduction occurred in 27/27 autopsied E2F-12/2
males and occurred in 1/11 of autopsiedwild-type males28 mg). In the most extreme cases, testis weight for
E2F-12/2 males was 10% of testis weight for wild-type by 15 months of age. Testicular atrophy has been ob-
served in 11% of C57BL/6 mice (Bronson, 1990), whilemales. Testicular atrophy had occurred as assessed by
bilateral testicular weight reduction (Figure 2B) and testicular teratocarcinomas, rather than atrophy, occur
frequently in129 mice (Stevens, 1973). The degenerationby histological appearance (Figure 2C). Histologically,
the testes in 2.5-month-old E2F-12/2 males appeared of the seminiferous tubules in the presence of Leydig
cells was unexpected, since the testosterone produc-healthy with numerous seminiferous tubules producing
abundant sperm (data not shown), which is consistent tion from Leydig cells is considered to be a critical stro-
mal signal necessary for productive spermatogenesiswith the fertility of young E2F-12/2 males. The only appar-
ent histological difference in the testes of young E2F- (Russell, 1990). Testicular atrophy in the E2F-12/2 ani-
mals may have occurred because of a pituitary or testic-12/2 males relative to that of young wild-type males was
the presence of more interstitial cells (Leydig cells) be- ular hormonal defect or perhaps a refractory state of
the seminiferous tubules to testosterone. Since sperma-tween the seminiferous tubules. By 9 months and be-
coming more evident in 12-month-old E2F-12/2 males, togenesis in rodents must decrease by 90% to affect the
number of progeny produced per litter (Russell, 1990),the testes contained empty and degenerated seminifer-
ous tubules. The number of empty tubules ranged from many of the E2F-12/2 males by 9±12 months of age were
most likely still fertile.several (Figure 2C, middle image) to almost all tubules
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Figure 2. Testicular Atrophy in E2F-12/2
Males
(A) Comparison of wild-type and E2F-12/2 tes-
tes. E2F-12/2 testes showed average (bottom
left) or severe (bottom right) reduction in size.
(B) Testicular atrophy in the E2F-12/2 males.
Average testicular weight of E2F-12/2 males
(open circles) was reduced bilaterally to 44%
the average testicular weight of wild-type ani-
mals (closed triangles) by 15 months of age.
(C) Histological sectioning (hematoxylin and
eosin [H and E]) of the testes shown in (A)
revealed degeneration of seminiferous tu-
bules (asterisks) and an increase in Leydig
cells (L) between the tubules of E2F-12/2 tes-
tes. Wild-type testes (left) display prominent
levels of spermatogenesis in all seminiferous
tubules. Moderately atrophied E2F-12/2 tes-
tes (bottom left in [A]) contained several
empty tubules percross-section (middle).Se-
verely atrophied E2F-12/2 testes (bottom right
in [A]) contained mostly collapsed and empty
seminiferous tubules (right), surrounded by
numerous Leydig cells. This small cluster of
active tubules was the only normal region
within this entire testis.
Exocrine Tissue Abnormalities a role in maintaining normal nuclear structure in this
All of the E2F-12/2 mice had submaxillary and parotid tissue as well.
salivary glands that werehistologically abnormal. In both Despite the changes in the salivary glands and pan-
of these tissues, cell nuclei were abnormally large and creas of E2F-12/2 animals, body weights measured at
swollen, and many cells were binucleate. The submaxil- 6.7 and 8.7 months of age were not perceptibly different
lary salivary gland is a mixed seromucous gland, which from those of wild-type littermates (data not shown).
concentrates salts and produces lubricating glycopro- However, between 12 and 15 months of age, a number
teins and lysozyme. In the submaxillary glands of E2F- of autopsied E2F-12/2 animals lost large amounts of
12/2 animals, the mucous cells contained irregular, large weight, corresponding in some males to as much as
nuclei (Figure 3A), while the serous cells were normal. 30%±40% of their weight at 8.7 months. Many of these
The abundance of mucous acini compared to serous autopsied animals had no obvious abnormalities other
acini within the submaxillary glands of E2F-12/2 animals than exocrine gland deterioration and fatty changes in
was low relative to that of wild-type animals. This de- the liver that often accompany drastic weight loss.
crease occurred despite an increase in the size of indi-
vidual mucous cells (Figure 3A). Interestingly, although
Tumor Formation in E2F-12/2 Animals
the mucous cells of the submaxillary gland were abnor-
Between 8 and 18 months of age, many E2F-12/2 ani-mal in E2F-12/2 animals, mucous cells of the sublingual
mals developed tumors (Table 1). Tumors observed in-salivary gland were normal. In the parotid salivary gland,
clude reproductive tract sarcomas, lung tumors, lym-which produces amylase for the digestion of starch,
phomas, and numerous other tumor types that werecells also contained abnormally large nuclei and often
found at a lower frequency. E2F-12/2 females and maleswere binucleate (Figure 3B). Likewise, the ex-
appeared to be comparably susceptible to tumor forma-orbital lacrimal gland of E2F-12/2 animals contained ab-
tion. A total of 35 tumors were observed out of 102normally large nuclei (data not shown). Histological ab-
autopsied E2F-12/2 animals. There are an additional 80normalities in the salivary glands became even more
surviving E2F-12/2 animals of this age cohort (originallypronounced in older E2F-12/2 animals, and the overall
182 animals). The expected total tumor incidence forsize of the salivary gland complex decreased with age
wild-type animals of variousgenetic backgrounds is only(data not shown).
0%±2% by 12 months and rises to 10% by 18 monthsOther exocrine tissues also appeared sensitive to the
(Bronson and Lipman, 1991). Since 34% (35/102) of au-loss of E2F-1. Abnormally large nuclei or nuclei doubled
topsied E2F-12/2 animals developed tumors mostlyin number were observed in the exocrine portion of the
within 15 months (Table 1), tumor development was ac-E2F-12/2 pancreas (Figure 3C). The zymogen granule
celerated in the absence of E2F-1. This estimated tumorcontent in the pancreas was low and the gross anatomi-
incidence of 34% ishigher than the true tumor incidence,cal appearance of the pancreas deteriorated in older
because in most cases (75%) sick E2F-12/2 animalsE2F-12/2 animals relative to that observed in wild-type
were chosen for autopsy. If no occult tumors are foundanimals. The presence of greatly enlarged nuclei in the
in the remaining 80 E2F-12/2 animals, then the tumorexocrine tissues of E2F-12/2 animals suggests that
incidence would be 19% (35/182). The actual tumor inci-E2F-1 helps maintain the normal nuclear structure and
dence lies between these two values (19% and 34%)possibly the correct DNA content within these tissues.
for animals at 18 months of age.Since nuclear size variation to a lesser extent also oc-
curred in the livers of E2F-12/2 animals, E2F-1 may have Since one-third of the tumors isolated from E2F-12/2
Mice Lacking E2F-1
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heterozygosity at the E2F-1 locus in one of the lung
tumors was not demonstrable by either Southern anal-
ysis or scrape PCR from histological sections. This
may be due to the presence of subtle mutations at the
E2F-1 locus that escaped detection or the presence of
normal tissue within the examined tumor specimen.
Reproductive Tract Sarcoma
Eleven E2F-12/2 virgin animals (8 females and 3 males)
between 12.7 and 16.5 (mean of 13.6; Table 1) months
of age developed aggressive sarcomas that appeared
grossly as large yellow/white masses in the reproductive
tracts. These tumors often attained a remarkable size
in the uterine horns (from 0.25 g to 5 g; Figure 4A, right
image) and sometimes in the ovaries of females, as well
as in the epididymis of males (Figure 4C, right image).
Reproductive tract sarcomas represent one-third of the
tumors found in the E2F-12/2 animals. In over 1000 mice
(Rb1/2 or P532/2 or Nf11/2 or control mice) produced with
the same hybrid 129 3 C57BL/6 genetic background
used in this study, no reproductive tract sarcoma has
been observed (Jacks et al., 1992, 1994; Williams et al.,
1994). In addition, this sarcoma was not seen in studies
following 1134 or 1577 mice of various genetic back-
ground for 24±30 months (Bronson and Lipman, 1991).
Histologically, thecellular compositionof the sarcoma
appeared quite uniform and nonglandular in the uterine
horns of females (Figure 4C) and epididymis of males
(Figure 4D). Tumor cells were densely packed at these
sites and occasionally small capillaries could be seen.
The most likely histological classification of the repro-
ductive tract sarcoma in females is either endometrial
stromal sarcoma (Dr. C. Fletcher, personal communica-
tion) or histiocytic sarcoma, between which a histologi-
Figure 3. Exocrine Gland Dysplasia in E2F-12/2 Animals cal identification in mice is difficult (Turusov and Mohr,
(A) Submaxillary salivary glands of E2F-12/2 mice are abnormal. 1994). Both endometrial stromal sarcomas and histio-
Histological staining (H and E) shows that the mucous acini of this cytic sarcomas in the mouse female reproductive tract
tissue (blue cytoplasm) contain greatly enlarged nuclei of irregular
can be induced chemically, but spontaneous develop-shape. The serous acini (pink cytoplasm, shown in the bottom right
ment is rare (Turusov and Mohr, 1994). Endometrial stro-corner) contain normal nuclei of uniform size. (Same magnification.)
mal sarcomas in mice and humans arise from the non-(B) Parotid salivary glands of E2F-12/2 mice also are abnormal.
Histological staining (H and E) reveals the irregularly enlarged and glandular mesenchymal component of the uterine
doubled nuclei. (Same magnification.) endometrium, which normally proliferates then sloughs
(C) The exocrine portion of the E2F-12/2 pancreas also contains in a cyclic manner (every 4±5 days in mice) in response
irregularly large nuclei. Histological staining (H and E) shows that
to hormones if embryo implantation has not occurred.nuclei are enlarged or doubled in number per cell. (Same magnifi-
Histiocytic sarcomas in mice arise from a macrophagecation.)
population and commonly present in the liver and
spleen; however in humans, histiocytic sarcoma is ex-
animals were reproductive tract sarcomas (see be- tremely rare. Furthermore, epididymal tumors in mice
low)Ðan extremely rare tumor in the 129 3 C57BL/6 and humans are very infrequent (Turusov and Mohr,
hybrid genetic background used in this studyÐthe ele- 1994). Also, the epididymal tumor in E2F-12/2 mice
vation of the incidence of this tumor is striking. The grows between the ducts carrying maturing sperm, in
tumor profile of E2F-12/2 mutants is unique, since the a space normally occupied by smooth muscle and con-
most common tumor is lymphoma for the C57BL/6 nective tissue without a stromal cell equivalent.
mouse strain (Bronson, 1990) and testicular teratocarci- In both females and males, the metastatic potential
noma for the 129 mouse strain (Stevens, 1973). of these tumors was quite high and could be followed
Several E2F-11/2 animals also developed tumors (Ta- easily by the tumor's canary yellow color (Figures 4E
ble 1). Four E2F-11/2 females developed reproductive and 4G). Six of the 11 E2F-12/2 animals with this tumor
tract sarcomas and 3 E2F-11/2 animals developed lung showed numerous metastases inmore than 4 abdominal
adenocarcinomas. The development of rare tumors al- organs, and all of these animals had metastases on the
ready observed in the E2F-12/2 animals and subse- diaphragm and omentum (a membrane to which the
quently in 7 E2F-11/2 animals suggested that loss of liver, spleen, and stomach are attached; Figure 4E). His-
heterozygosity at the E2F-1 locus may have occurred tologically, the tumor cells were highly invasive, pene-
trating deep into the pancreas (Figure 4F), kidney, liver,in the tumors of the E2F-11/2 animals. However, loss of
Cell
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Table 1. Tumors Arising in E2F-1 Mutant Mice
No. in No. in
Tumor Type E2F-12/2 (F, M) Age (Months) E2F-11/2 (F, M) Age (Months)
Reproductive tract sarcoma 11 13.6a 4 17.1a
Uterine (8, 2) 12.7, 12.8, 12.9, 12.9, 12.9, 13.6, 15.4, 16.5 (4, 2) 15.7, 16.7, 17.0, 19.0
Epididymal (2, 3) 12.7, 12.9, 14.6
Lung adenocarcinoma 7 (3, 4) 8.8, 12.0, 12.8, 13.6, 15.9, 17.2, 17.9 3 (1,2) 13.4, 16.7, 17.0
Lymphomas 8 (4, 4) 12, 13.4, 15, 15, 15.4, 15.9, 16.2, 16.5 2 (2, 2) 18.8, 19.5
Hemangiosarcoma 2 (1, 1) 8.0, 14.0 1 (1, 2) 16.0
Histiocytic sarcoma 2 (2, 2) 11.0, 13.5
Basal cell tumor 1 (1, 2) 11.3
Leiomyosarcoma 1 (1, 2) 12.8
Teratoma 1 (1, 2) 14.1
Myxosarcoma 1 (1, 2) 17.0
Unidentified tumor 1 (2, 1) 14.1
Pituitary adenoma 0 1 (1, 2) 18.1
Hepatoma 0 1 (2, 1) 20.0
Harderian gland adenoma 0 1 (2, 1) 15.3
Total 35 (20, 15) 13 (9, 4)
a Mean.
Figure 4. Reproductive Tract Sarcomas in E2F-12/2 Females and Males
(A) Highly aggressive sarcomas (right) developed in the uterine horns (u) and often ovaries (o) of E2F-12/2 females, which massively increased
the size of the reproductive tract compared with that from a wild-type female (left). Photos were taken at the same scale. Canary yellow
patches were evident on the surface and through this tumor.
(B) Histological sectioning (H and E) of the reproductive tract sarcoma in E2F-12/2 females.
(C) This reproductive tract sarcoma was also found in the lower epididymis of E2F-12/2 males. Left and right images show the epididymis (e)
and atrophied testes (t) from the same E2F-12/2 male. The left image shows a normal epididymis, while the right shows the epididymal tumor,
with the same canary yellow patches as in the uterine tumor.
(D) Histological sectioning (H and E) of the reproductive tract sarcoma in E2F-12/2 males. The same histological pattern is observed in both
the female and male reproductive tract sarcomas.
(E) Numerous canary yellow metastases (m) were observed in the abdominal cavities of E2F-12/2 animals with the reproductive tract sarcoma.
The mesenteric nodes near the small intestine and the pancreas and omentum were frequently overtaken by the growth of the sarcoma
(shown). Liver and diaphragm also had yellow metastases (not shown).
(F) Histological sectioning (H and E) of metastases in the pancreas of the E2F-12/2 female shown in (A). The sarcoma (pink cells) has grown
between two lobes of the exocrine portion of the pancreas (red cells).
(G) Many additional canary yellow metastases (m) can be seen on the surface of the kidneys and in the retroperitoneal nodes.
(H) Histological sectioning (H and E) of the retroperitoneal nodes from the E2F-12/2 female shown in (A) reveals the sarcoma invading the
parenchyma of the node. Note the increased size and abundant cytoplasm of the tumor cells (pink).
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fat, and regional lymph nodes (Figure 4H). In 2 cases
metastases were found in the lungs. While the majority
of the metastases appeared histologically similar to the
primary tumors in the uterine horns or epididymis, the
metastases in fat or in lymph nodes (Figure 4H) con-
tained cells with abundant cytoplasm and distinct bor-
ders, which simply may reflect the packing density pos-
sible in these tissues. Spontaneous tumor metastases
of solid tumors inmice are rare (R. Bronson, unpublished
observation), and thus, the ability of the E2F-12/2 repro-
ductive tract sarcomas to metastasize is noteworthy.
Lung Tumors
Seven of the autopsied E2F-12/2 animals between 8.8
and 18 months of age developed lung tumors (up to 1.5
cm in diameter) that often occupied half of the thoracic
cavity (Figure 5A; Table 1). These tumors were classified
as highly invasive lung adenocarcinomas or generally
as non-small-cell lung carcinomas. In most cases, the
gross anatomical architecture of the several major lung
lobes as well as the architecture of the smaller mediasti-
nal lung lobes was deformed by the tumor growth. In
other studies, only 1 lung adenocarcinoma was seen in
over 1000 mice (Rb1/2, p532/2, Nf11/2, or control mice)
with the hybrid 129 x C57BL/6 genetic backgound used
in this study (Jacks et al., 1992, 1994; Williams et al.,
1994). Similarly, lung adenocarcinomas were not ob-
served in 1134 mice of various genetic backgrounds
followed over a 24 month period (Bronson and Lipman,
1991).
Histologically, the normal lace-like alveolar space
(Figure 5B, upper image) was overtaken by the ex-
panding tumor (Figure 5B, lower image). From the same
mutant animals, lung lobes which at first appeared
grossly normal were later identified as containing
smaller islands of tumor cells (Figure 5B, middle image)
that had most likely metastasized from the neighboring
affected lung lobes. Smaller islands of tumor often were
surrounded by numerous alveolar histiocytes. Less se-
vere lung adenomas (1±2 mm) were commonly seen in
Figure 5. Lung Adenocarcinomas in E2F-12/2 Animalsthe E2F-12/2 autopsied animals (data not included in
(A) Massive lung tumors were often isolated from E2F-12/2 animalsTable 1) and also in wild type animals.
that occupied more than half the thoracic cavity (right). Lungs from
a wild-type animal (left) are shown for comparison.
Lymphoproliferation and Lymphoma (B) Histological sectioning (H and E) detected a glandular architec-
Between 8 and 15 months, a small fraction of the ture in these lung tumors consistent with that of a broncho-alveolar
adenocarcinoma. The normal lace-like alveolar space in the lungE2F-1 homozygous (5/32 5 15.6%) and heterozygous
(top) became infiltrated with many small islands of tumor (asterisks)(3/23 5 13%) autopsied females developed a lympho-
with numerous histiocytes (middle) or became overtaken with tumorproliferative syndrome that often resulted in death. Af-
mass (lower).
fected animals displayed enlarged lymph nodes (Figure
6A), splenomegaly (from 0.1 g up to 1.0±4.3 g; Figure
young E2F-12/2 animals, were not detected on periph-6B), anemia (hematocrits were reduced from 40%±45%
eral T cells from young animals or on thymocytes fromto 8%±15%), and glomerulonephritis of the kidneys
older animals. Although lpr mice and gld mice, which(data not shown). This occurred in one wild-type female
have naturally occurring mutations in Fas and the Fasas well. Although environmental factors may have influ-
ligand respectively, develop a lymphoproliferative stateenced the development of lymphoproliferation, we ex-
with generalized lymph node enlargement, splenomeg-amined lymphocyte populations from wild-type and
aly, and glomerular nephritis, Fas levels in E2F-12/2 ani-E2F-12/2 animals for possible differences. Fluoresence-
mals were not consistently affected (data not shown).activated cell sorter analysis of lymphocytes from thy-
Lymphoproliferation may have been a preneoplasticmus, spleen, and lymph nodes of young and old animals
condition in the E2F-12/2 animals, since 8 E2F-12/2 ani-demonstrated that most B and T lymphocyte surface
mals between 12 and 16.5 months of age developedmarkers were normal (data not shown). Moderate differ-
lymphomas (Table 1). Five of these E2F-12/2 animalsences in the T-cell receptor±associated signaling mole-
cule, CD3e, which were apparent on thymocytes from developed follicular center cell lymphomas in enlarged
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from the testicular atrophy and salivary gland dysplasia
observed. Overt malformation is not observed even in
normal E2F-12/2 tissues from which tumors and hyper-
plasia develop. At the simplest level this must indicate
that tissues such as the testis and salivary gland rely
heavily on the correct function of E2F-1 and that this
E2F-1 function cannot be replaced in all tissues by other
cellular activities.
Tissue and Temporal Specificity
Given the known capacity of E2F-1 to stimulate cellular
proliferation and to act as an oncogene, we anticipated
that one possible outcome from inactivating the E2F-1
locus might have been decreased proliferation. Another
possible outcome might have been less apoptosis, in
light of the capability of E2F-1 to induce apoptosis. Still
another possibility is that inactivation of the E2F-1 locus
might have compromised the ability of pRB to suppress
proliferation, therefore leading to hyperproliferation.
While examining the E2F-12/2 mice, we were struck by
the radically different cellular and tissue responses to
the loss of E2F-1. In exocrine cells, we have detected
abnormally large and doubled nuclei, which may have
undergone DNA replication without cell division. In the
testes of E2F-12/2 mice, tissue atrophy correlates with
loss of seminiferous tubules. In a subset of affected
Figure 6. Lymphoproliferation and Lymphoma mice, dramatic lymphocyte proliferation is seen. Most
(A) Comparison of a wild-type axial lymph node (leftmost) and nu- surprisingly, several different tissues develop aggres-
merous axial lymph nodes from an E2F-12/2 female. Scale bar is 5 sive tumors. Discovering the molecular reasons for each
mm. This E2F-12/2 female also had many more enlarged cervical of these pathologies will enable us to compare the
and retroperitoneal lymph nodes.
causes for the different tissue responses. However, even(B) Splenomegaly (10-fold) in an E2F-12/2 female (top) relative to a
at a phenotypic level it is clear that correct E2F-1 func-spleen from a wild-type female (bottom) is shown. Splenomegaly
tion is important in several types of cells and tissues.ranged from 4- to 43-fold in E2F-12/2 and E2F-11/2 females.
(C) Two greatly enlarged mesenteric nodes from two E2F-12/2 males Field and coworkers (1996 [this issue of Cell ]) also have
with follicular center cell lymphoma are shown with a normal mesen- inactivated E2F-1 mice and report a defect in thymocyte
teric node (bottom right) for comparison. apoptosis that results in hyperproliferation. They also
Scale bars are 5 mm.
observed that their older E2F-12/2 mice undergo testicu-
lar atrophy. A single effector function of E2F-1 cannot
explain the diverse outcomes seen in all of the affectedmesenteric nodes (up to 1.5 cm in diameter; Figure 6C).
The incidence for lymphoma is7.8% (8/102) of autopsied tissues,and thuseventually we must consider the poten-
tial functions of E2F-1 in each of these separate tissues.E2F-12/2 animals. The expected frequency is 1.5% by
18 months in mice of various genetic backgrounds There are several possibilities as to why the defects
observed in the E2F-12/2 mutants show tissue and tem-(Bronson and Lipman, 1991).
poral specificity. At a biochemical level, the different
tissue specific responses to the loss of E2F-1 suggestDiscussion
three possible mechanisms: E2F-1 regulates different
genes in different tissues; E2F-1 controls expression ofE2F-1 Is Not Required for Viability
or Normal Development the same genes differently in the various tissues, per-
haps in combination with tissue specific factors; or tis-The normal development and the fertility of the E2F-
12/2 mice demonstrate that the function of E2F-1 is not sues respond differently to the same target genes regu-
lated by E2F-1. Temporal changes in E2F-1-dependentrequired for either cell or animal survival. If E2F-1 is
important for viability, then this E2F-1 function lost by gene regulation add another variable to these mecha-
nisms. To begin to analyze why the affected tissues areinactivation of the E2F-1 locus must have been masked,
perhaps by the continued action of other E2F family sensitive to the loss of E2F-1, it will be important to
delineate the expression pattern for all E2F family mem-members. Eventually, the production of mice deficient
for other E2F family members will allow us to test bers relative to one another and to identify the actual
E2F-1 target genes in the affected tissues.whether the E2F family is essential. Despite the viability
of E2F-12/2 mice, specific tissues in all E2F-12/2 mice An additional level of complexity comes from the real-
ization that a transcriptional response mediated throughwere sensitive to the loss of E2F-1. Loss of E2F-1 does
not induce grossly abnormal development, but rather E2F sites may be either activation or repression, de-
pending on the promoter contexts in which the E2F sitesin a subset of tissues leads to subtle aberrations that
become increasingly more obvious with time, as evident lie (Weintraub et al., 1992). Deletion or mutation of E2F
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sites within promoters can lead to decreases (i.e., DHFR growth suppressive properties. Interestingly, the E2F-1
gene on mouse chromosome 2 maps near the agouti Apromoter) or increases (e.g. b-myb and E2F-1) in tran-
scription (Blake and Azizkhan, 1989; Means et al., 1992; locus that determines coat color (Li et al., 1994; K. Helin
and N. Jenkins, unpublished data). Since the agouti le-Lam and Watson, 1993; Hsiao et al.,1994; Johnson et al.,
1994b; Neuman et al., 1994). Decreases in transcription thal yellow allele, Ay, is associated with spontaneous
tumors and has a 120±170 kb deletion (Duhl et al., 1994;following E2F site mutation correspond to the loss of
E2F-dependent transactivation, while increases in tran- Michaud et al., 1994), E2F-1 expression may be altered
in mice carrying this rearranged Ay allele.scription following E2F site mutation likely result from
the loss of repression by pocket protein/E2F com- The tissues affected by tumorigenesis also argue for
specific differences in the response to the loss ofplexes.
The dual nature of E2F sites to act positively or nega- E2F-1. As observed for testicular atrophy and exocrine
gland dysplasia, tumor development occurs only in spe-tively may allow E2F-1 to perform vastly different tasks
in vivo depending on the function of the target gene. cific sites. The tissues that are common sites of E2F-1-
mediated tumorigenesis must rely more heavily onFirst, consider E2F-1 as an activator. If E2F-1 transacti-
vates target genes that stimulate cell cycle progression E2F-1 than other tissues. This same argument fits well
with the observed tissue-specific development of tu-(e.g. cyclin E, other E2Fs) or prolong cell survival, then
loss of E2F-1 may decrease the cycling cell population. mors seen with inheritance of other tumor suppressor
gene mutations.In contrast, if E2F-1 transactivates target genes that
increase apoptosis (e.g. c-myc) or facilitate differentia-
tion (possibly pRB itself), then loss of E2F-1 may in-
A pRB/E2F-1 Tumor Suppressor Complexcrease the cycling cell population. Alternatively, if we
Tumor development in the E2F-12/2 mice most likelyconsider pRB/E2F-1 as a repressor, then loss of E2F-1
results from the loss of pRB/E2F-1-mediated growthand the subsequent loss of pRB/E2F-1-mediated re-
suppression, which is consistent with the biochemicalpression of target genes may lead to outcomes, which
evidence for pRB/E2F-1 complex formation in vitro andare now opposite to those predicted for E2F-1 as an
in vivo. Loss of growth suppression by the loss of aactivator. In tumors, loss of E2F-1 may increase the
pRB/E2F-1 complex strongly suggests that pRB/E2F-1cycling cell population, which in combination with the
actively represses key promoters by occupying E2Faccumulation of additional mutations, results in malig-
sites. Recent work suggests that repression by pRB/nancy. At this time however, there is no evidence for
E2F DNA-bound complexes appears to block both E2F-either a cell-autonomous or non-cell-autonomous path-
mediated transactivation and also transactivation medi-way to atrophy or tumor development.
ated by other transcription factors (Weintraub et al.,
1992, 1995; Flemington et al., 1993; Helin et al., 1993;E2F-1 Is a Tumor Suppressor Protein
Adnane et al., 1995; Bremner et al., 1995; Qin et al.,The development of tumors in E2F-12/2 animals strongly
1995; Sellerset al., 1995). We propose that active repres-argues that E2F-1 is a previously unrecognized tumor
sion by a pRB/E2F-1/DP tumor suppressor complexsuppressor protein. The increased incidence of tumors
bound to key promoters is lost in the E2F-12/2 animalsin E2F-12/2 animals is impressive, especially consider-
and predisposes to tumor formation.ing the age at which tumors were detected and the size,
Clearly, the loss of E2F-1 is not equivalent to the lossthe invasiveness, and the high metastatic potential of
of pRB, which in mice is lethal (Clarke et al., 1992; Jacksthe tumors. The frequency of reproductive tract sarcoma
et al., 1992; Lee et al., 1992). Even the tumors seen insuggests that E2F-1 has a key growth suppressive role
the E2F-12/2 mice (Table 1) are distinct from the pituitaryin the uterine horns of females and the epididymus of
adenomas (Jacks et al., 1992) and thyroid tumors (Wil-males. However, the incidence and long latency for the
liams et al., 1994) arising in Rb1/2 mice. Only one autop-development of these tumors indicates that additional
sied E2F-11/2 animal developed a pituitary adenoma.mutations are required. The extent of the metastasis
While many of the E2F-12/2 mice develop lung adeno-from the reproductive tract to numerous abdominal or-
carcinomas, Rb1/2 mice develop only a low levelof bron-gans suggests that E2F-1 normally may repress genes
chial epithelium hyperplasia (Williams et al., 1994). Thethat facilitate, or activate genes that inhibit, metastasis.
human tumors in which RB1 mutations are found com-Alternatively, the reproductive tract sarcoma may be a
monly, such as retinoblastomas, osteosarcomas, smallhighly metastatic tumor with or without the loss of
cell lung carcinomas, and carcinomas of breast, blad-E2F-1.
der, and prostate (Riley et al., 1994; Weinberg, 1995),Although no human disease has been mapped to
also were not observed in the E2F-12/2 mice.the chromosomal position of human E2F-1 at 20q11,
We expected the E2F-12/2 phenotype to differ fromE2F-1 gene amplification with overexpression in an
the Rb1/2 or Rb2/2 phenotype in mice for several reasons.erythroleukemic cell line and translocation of the
First, loss of pRB leads to the derepression of E2F-1,E2F-1 locus with very low E2F-1 expression in mono-
E2F-2, and E2F-3 simultaneously, while loss of E2F-1blastic cell lines have been identified (Saito et al., 1995).
may lead to derepression and loss of activation of E2F-These data suggest that abnormal changes in E2F-1
1-specific target genes. Secondly, pRB binds many dif-expression may be involved in human tumor develop-
ferent transcription factors besides E2F (Riley et al.,ment. Furthermore, the E2F-1 gene at 20q11 lies near
1994; Horowitz and Udvadia, 1996) and dysregulation ofthe pRB-relatedp107 gene at 20q11.2 (Saito et al., 1995),
these factors may result in the Rb2/2 or Rb1/2 phenotype.so that chromosomal rearrangements involving this re-
gion potentially may inactivate two gene products with Thirdly, Rb1/2 mice die from pituitary tumors at a mean
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domain exon), was modified with SalI linkers and was subclonedage of 11 months (Williams et al., 1994), which may
into the XhoI site of the pPNT targeting vector (Tybulewicz et al.,preclude the later development of reproductive tract
1991). A 2.1 Kbp intron fragment extending from the SphI site up-tumors and lung adenocarcinomas. Thus, a lack of con-
stream of exon 2 to amino acid 89 (equivalent to amino acid 94 in
cordance between pRB and E2F mutant phenotypes human E2F-1) within exon 2 was generated by PCR, modified with
does not imply necessarily that E2F-1 is suppressing KpnI linkers and subcloned into the KpnI site of pPNT between the
neoR and thymidine kinase genes. The resultant targeting vector hasgrowth through a pRB-independent mechanism.
deleted a portion of exon 2 and all of exon 3 that encode the basicMalignancy associated with the loss of E2F-1 sug-
domain and DNA binding domains, respectively. Deleted codonsgests that loss of the other pRB-regulated E2F proteins,
correspond to amino acids 89±186 for mouse E2F-1, that are equiva-E2F-2 and E2F-3, may predispose to tumor formation
lent to amino acids 95±191 for human E2F-1. Since the 39 end of
as well, perhaps with unique tissue specificities. Since the neoR gene contains translational stops in all reading frames, the
neither p107 or p130 mutations are known to be associ- disrupted exon 2 should cause the premature translational termina-
tion of E2F-1. If the disrupted exon 2 is removed by alternativeated with human tumors, the loss of E2F-4 or E2F-5 may
splicing, then a mutant polypeptide may be translated that still lacksor may not contribute to tumorigenesis. However, given
cyclin A binding and DNA binding activities. No such product wasthe complex networks connecting the various E2Fs,
detected.cyclins, and pocket proteins, many perturbations in this
E2F-dependent regulatory matrix may result in tumor Homologous Recombination in ES Cells
formation. and Chimaera Production
The E2F-1 targeting vector was linearized and electroporated into
D3 embryonic stem cells. Clones doubly resistant to G418 (300 mg/E2F-1 Is an Oncogene and a Tumor Suppressor
ml) and gancyclovir (2 mM) were tested for homologous recombina-While overexpression of E2F-1 was known to transform
tion by Southern analysis. Two genomic probes were used to con-fibroblasts to beoncogenic, this work demonstrates that
firm that homologous recombination had occurred using KpnI or
loss of E2F-1 also predisposes to tumorigenesis and EcoRI digests. A neoR gene probe was used to ensure that random
strongly suggests that we reclassify E2F-1 as a tumor integration of the targeting vector had not occurred elsewhere in
suppressor as well as an oncogene. To our knowledge, the genome. Two E2F-11/2 ES cell clones were used to produce
chimaeras with >90% agouti coats.this is the first example of a gene product that is able
to induce tumors either by overexpression of the wild-
Matings for Mutant Progenytype protein or by a loss-of-function mutation.
Male chimaeras from both clones produced F1 agouti animals, 50%
How can E2F-1 be both an oncogene and a tumor of which were F1 heterozygotes. Male and female F1 heterozygotes
suppressor? If the absolute level of E2F-1 is critical for identified by Southern or genomic PCR analysis were interbred to
its correct action, then overexpression of E2F-1 or loss produce F2 progeny. A genomic PCR assay (Figure 1C) to detect
the wild-type allele (392 bp) or the mutant E2F-1 allele (167 bp) wasof E2F-1 could be tumorigenic by leading to inappropri-
designed using a common L31 intron primer (59GCTGGAATGGTGTate overexpression of the same target gene. Alterna-
CAGCACAGCG 39) and the E2F-1 wild-type exon L26 primertively, E2F-1 may regulate multiple growth-promoting
(59TCCAAGAATCATATCCAGTGGCT39) or the neoR gene L28 primergenes, some by E2F-1 activation and some by E2F-1
(59CTACCCGGTAGAATTGACCTGCA 39). PCR reactions (25 ml) were
repression. If either E2F-1-activated genes or E2F-1- amplified with pyrostase (Molecular Genetic Resources) for 39 cy-
repressed genes can drive proliferation, then gain or cles (948C, 1 min; 588C, 1 min; 728C, 1 min) and 1 cycle (728C, 7
min), then analyzed on a 1.6% agarose gel.loss of E2F-1 function is tumorigenic. Formally however,
E2F-1 has not been shown to be an oncogene and tumor
Immunoprecipitation±Western Analysis for E2F-1suppressor gene in the same experimental setting, and
Mouse embryo fibroblasts from 12.5-day-old embryos were starvedtumor formation with transformed fibroblasts in nude
with 1%±2% fetal bovine serum in Dulbecco's modified Eagle's
mice is significantly different from spontaneous tumor medium for 45 hr, then released into 10% fetal bovine serum for 20
development. hr. Extracts were prepared and mixed with protein A±sepharose
The capacity of E2F-1 to act as an oncogene and a to which monoclonal antibodies (PAB419 [anti-SV40 T antigen] or
KH129 [anti-E2F-1, K. Helin]) or polyclonal sera (normal rabbit serumtumor suppressor creates a novel situation that could
or anti-RBP3 peptide anti-serum [Helin et al., 1992]) had been cou-occur any time a key regulator meets three criteria. It
pled covalently (Harlow and Lane, 1988). After immunoprecipitationmust have both a positive function and a negative func-
for 4 hr at 48C, beads were washed and bound proteins were ana-
tion for a rate-limiting step(s) in tumorigenesis, and a lyzed by SDS±polyacrylamide gel electrophoresis and Western blot-
null mutation must not block proliferation. E2F-1 fulfills ting with the monoclonal antibodies KH22 and KH102 (K. Helin),
these three criteria, because E2F-1 both transactivates which recognize E2F-1. A recombinant mouse E2F-1 bacterial lysate
was used as a positive control for Western blotting antibodies.and represses genes required for proliferation, and
E2F-1 is not required for viability or proliferation. There-
Autopsy and Histopathologyfore, gain-of-function and loss-of-function mutations
Between 8 and 18 months, 102 E2F-12/2 animals were autopsied.
promote proliferation and enhance tumorigenesis. Any Animals were autopsied in most cases (75%) because they had lost
gene whose product can serve this dual role will likely weight and appeared in poor health or had a palpable abnormality.
be both an oncogene and tumor suppressor. All tissues were examined from 83 E2F-12/2 animals regardless of
their pathologic status. Tissues were formalin fixed, dehydrated,
and embeddedin paraffin according to standard protocols. SectionsExperimental Procedures
(4±5 mm) were stained with hematoxylin and eosin and examined
microscopically.Construction of a Targeting Vector
A 129 mouse genomic phage clone containing the E2F-1 gene was
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